ASA Resource plunges as its finds evidence of corruption at Zimbabwean asset
On the plus side, the board is pretty certain there have been no thefts of gold from the gold room at FRGM, or shipments of gold ore to China.
Company
Faron Pharmaceuticals Limited
LON:FARN
Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. The company’s lead asset bexmarilimab is currently being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments.
418 stories · page 20 of 21
Faron teams up with University of Birmingham for Clevegen liver cancer clinical program
The two will work together to develop and initiate a liver cancer program testing Clevegen in clinical trials
FTSE 100 down 164 points on snap election news; pound hits 10-week high
The UK prime minister has announced a snap general election for 8 June
Archive
Proactive News round-up: Obtala, Sabien Technology, Sound Energy ...
A glance at some of the stories on the Proactive newswire today
Long wait to supply Airbus is over for Hardide
Some of the largest risers and fallers in London at 3.15pm
Drug developer Faron Pharmaceuticals' annual results statement charts a year of major landmarks
Traumakine, used to treat acute respiratory distress syndrome, is undergoing a phase III clinical trial with results expected in the second half.
Archive
Have a break, have a Brexit
Article 50 will be triggered on Wednesday but there is still a lot of horse trading to be done over the coming months before Britain's departure from the EU is settled
ValiRx and Faron highlight different sides of pharma funding
Some the largest rises and fall at 3pm: ValiRx, Faron, Jersey Oil
FTSE stocks mark record highs with Wall St as Trump boosts construction, commodity stocks
FTSE 100 stocks, just like Wall Street, defied soothsayers’ prognoses that investors didn’t much like a threadbare speech to Congress from US President Donald Trump overnight, and pledged their vote to his spending ambitions as record heigh
Archive
Webis sales rise not enough to offset margin concerns
Some the largest share price rises and fall in London at 3pm: Webis, Wey Education, ValiRx
Faron Pharmaceuticals raises £5mln in premium placing
The new funds will be used to expand the pre-clinical and early-clinical development of the company’s immuno-oncology drug, Clevegen
EQTEC steps on gas as parent converts loan
Some of the largest rises and falls in London at 3.15pm: EQTEC, Goldplat, Feedback
Faron Pharmaceuticals drug Traumakine goes into phase II clinical trials for second major indication
The drug is currently undergoing a phase III study in patients with acute respiratory distress syndrome after delivering some remarkable results earlier in its development.
Investments and investor services
FTSE closes flat as Unilever holds market back
The FTSE 100 ended flat on Monday as Unilever shares sank in the wake of Kraft Heinz saying it had abandoned its proposed merger which would have been one of the biggest in corporate history
Archive
Proactive news highlights: featuring Corero Network Security, Redx Pharma, Faron Pharmaceuticals and more…
Corero off to fast start in 2017 with contract win; Redx Pharma unveils plans to raise up to £14.9mln; Faron Pharma is ‘excited’ for the coming year; plus much more…
Faron Pharmaceuticals 'excited' about key year as it gears up for successful completion of clinical trial
Faron believes its drug, Traumakine, could revolutionise the intensive care treatment for patients with acute respiratory distress syndrome – a lung condition that currently has a high death rate.
Four drug stocks to watch in phase III next year
2017 could be a big year for these four lesser-known junior drug developers
Small Cap highlights: Sareum leads Monday’s stand-out small cap biotech stocks
Sareum, Faron, WideCells, Abzena and Ergomed were among Monday's small cap highlights
Recruitment starts in Japan for pivotal trial for Faron's Traumakine
The Japanese Phase III trial will significantly increase the total number of patients in Traumakine pivotal studies